Institutional members access full text with Ovid®

Share this article on:

Consensus Review of the Treatment of Cardiovascular Disease in People With Hemophilia A and B

Ferraris, Victor A. MD, PhD*; Boral, Leonard I. MD, MBA; Cohen, Alice J. MD; Smyth, Susan S. MD, PhD§; White, Gilbert C. II MD

doi: 10.1097/CRD.0000000000000045
Review Articles

With advances in care, increasing numbers of people with hemophilia (PWH) achieve near-normal life expectancies and present with typical age-related cardiovascular conditions. Evidence-based guidelines for medical or surgical management of cardiovascular conditions in individuals with hemophilia are limited. Published recommendations exist for the management of some common cardiovascular conditions (eg, ischemic heart disease, atrial fibrillation), but identifying optimal strategies for anticoagulant or antithrombotic therapy constitutes the primary challenge of managing nonoperative cardiovascular disease (CVD) in PWH. In general, as long as factor concentrates or other hemostatic therapies maintain adequate hemostasis, the recommended medical and surgical management of CVD in PWH parallels that in individuals without hemophilia. The presence of factor inhibitors complicates hemophilia management. Published outcomes of CVD treatment in PWH are similar to those in the general population. Specific knowledge about factor replacement, factor inhibitors, and disease-specific treatment distinguishes the cardiovascular care of PWH from similar care of individuals without this rare bleeding disorder. Furthermore, a multidisciplinary approach incorporating a hematologist with an onsite coagulation laboratory, ideally associated with a hemophilia treatment center, is integral to the management of CVD in PWH.

From the *Division of Cardiovascular and Thoracic Surgery, University of Kentucky Chandler Medical Center, Lexington, KY; Department of Pathology and Laboratory Medicine, University of Kentucky Chandler Medical Center, Lexington, KY; Division of Hematology and Oncology, Newark Beth Israel Medical Center, Newark, NJ; §Division of Cardiovascular Medicine, University of Kentucky Gill Heart Institute, Lexington, KY; and Blood Research Institute, BloodCenter of Wisconsin, Milwaukee, WI.

Disclosure: Victor A. Ferraris has been a paid consultant for Baxter Healthcare (CME activity), Haemonetics (advisory board), and AstraZeneca (advisory board). Leonard I. Boral has previously been a paid consultant for Alexion Pharmaceuticals. Alice J. Cohen and Susan S. Smyth declare no competing interests. Gilbert C. White is a paid consultant for Bayer (grant review); Baxter (Data Safety Monitoring Board); and CSL Behring, Novo Nordisk, and Pfizer (advisory boards); is a cofounder of and scientific advisory board member for Entegrion; and is on the scientific advisory board for Asklepios.

Correspondence: Victor A. Ferraris, MD, PhD, Tyler Gill Professor of Surgery, Division of Cardiovascular and Thoracic Surgery, University of Kentucky Chandler Medical Center, Kentucky Clinic, Suite A301, 740 South Limestone, Lexington, KY 40536-0284. E-mail: ferraris@uky.edu.

This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives 3.0 License, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially.

Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.